The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2003-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JC.2003-030738PMID 14557471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

  2006cited by this paper
• The genetic abnormality in the beta cell determines the response to an oral glucose load

  2002cited by this paper
• A genetic switch in pancreatic beta-cells: implications for differentiation and haploinsufficiency.

  2002cited by this paper
• Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

  2002cited by this paper
• Loss of HNF-1alpha function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism.

  2001cited by this paper
• Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

  2001cited by this paper
• Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes.

  2001cited by this paper
• Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

  2000cited by this paper
• Defective Pancreatic β-Cell Glycolytic Signaling in Hepatocyte Nuclear Factor-1α-deficient Mice*

  1998cited by this paper
• Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1

  1998cited by this paper
• Defective pancreatic beta-cell glycolytic signaling in hepatocyte nuclear factor-1alpha-deficient mice.

  1998cited by this paper
• The pathogenesis of NIDDM involves a defective expression of the GIP receptor

  1997cited by this paper
• Novel MODY3 Mutations in the Hepatocyte Nuclear Factor-1α Gene: Evidence for a Hyperexcitability of Pancreatic β-cells to Intravenous Secretagogues in a Glucose-Tolerant Carrier of a P447L Mutation

  1997cited by this paper
• GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.

  1996cited by this paper
• Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

  1995cited by this paper
• The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis.

  1994cited by this paper
• Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

  1994cited by this paper
• The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.

  1994cited by this paper
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  1993cited by this paper
• Gut hormones and diabetes mellitus.

  1992cited by this paper
• Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

  1991cited by this paper
• Signal transmission after GLP-1(7-36)amide binding in RINm5F cells.

  1989cited by this paper
• Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

  1986cited by this paper
• Pancreatography in chronic pancreatitis: international definitions.

  1984cited by this paper
• The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera.

  1984cited by this paper
• Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics.

  1983cited by this paper

• GIP is back

  2026cites this paper
• GIP. Le retour en grâce

  2026cites this paper
• The Glycemic Impact of Protein Ingestion in People With Type 1 Diabetes.

  2025cites this paper
• The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut-bone axis.

  2025cites this paper
• From incretin discovery to anti-obesity blockbuster drugs. One hundred years of research to move from shadow to spotlight

  2025cites this paper
• Glucose-dependent insulinotropic polypeptide (GIP)

  2025cites this paper
• GLP-1 and GIP may play a role in long-term weight trajectories after gastric bypass

  2025cites this paper
• β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2 Diabetes.

  2025cites this paper
• Proglucagon-derived Peptides: Human Physiology and Therapeutic Potential.

  2025cites this paper
• Altered GIP/GLP-1 Secretion Ratio is Associated With Impaired β Cell Function in Humans

  2025cites this paper
• Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration

  2024cites this paper
• GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

  2024cites this paper
• Evaluating GIP and glucagon as key regulators of insulin secretion in the pancreatic islet.

  2024cites this paper
• GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology.

  2024cites this paper
• The Role of GLP-1, GIP, MCP-1 and IGFBP-7 Biomarkers in the Development of Metabolic Disorders: A Review and Predictive Analysis in the Context of Diabetes and Obesity

  2024cites this paper
• Design of a novel long-acting dual GLP-1/GIP receptor agonist.

  2024cites this paper
• Safety of native glucose-dependent insulinotropic polypeptide in humans.

  2024cites this paper
• Effect of gut hormones on bone metabolism and their possible mechanisms in the treatment of osteoporosis

  2024cites this paper
• Glycemic variability in chronic calcific pancreatitis with diabetes mellitus and its possible determinants.

  2024cites this paper
• Altered desensitization and internalization patterns of rodent versus human glucose‐dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge

  2024cites this paper
• De la découverte des incrétines aux blockbusters coupe-faim. 100 ans de recherches pour arriver sous les feux de l’actualité thérapeutique

  2024cites this paper
• Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management

  2023cites this paper
• The intestine as an endocrine organ and the role of gut hormones in metabolic regulation

  2023cites this paper
• The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans.

  2023cites this paper
• The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide

  2023cites this paper
• Interactions between the regulatory peptide 26RFa (QRFP) and insulin in the regulation of glucose homeostasis in two complementary models: The high fat 26RFa-deficient mice and the streptozotocin insulin-deficient mice.

  2023cites this paper
• ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the incretin polypeptide GIP

  2022cites this paper
• Comprehensive evaluation of patterns of hypoglycemia unawareness (HUA) and glycemic variability (GV) in patients with fibrocalculous pancreatic diabetes (FCPD): A cross-sectional study from South India

  2022cites this paper
• The Gut-Bone Axis in Diabetes

  2022cites this paper
• Nexus between constructs of social cognitive theory model and diabetes self-management among Ghanaian diabetic patients: A mediation modelling approach

  2022cites this paper
• Study of relationship between glucagon level, glycemic status, and β-cell function in newly diagnosed T2DM patients, treated with insulin

  2022cites this paper
• The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction

  2022cites this paper
• Acute concomitant glucose‐dependent insulinotropic polypeptide receptor antagonism during glucagon‐like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity

  2022cites this paper
• Effects of GLP-1 and GIP on Islet Function in Glucose Intolerant, Pancreatic Insufficient Cystic Fibrosis.

  2022cites this paper
• The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

  2022cites this paper
• The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

  2022cites this paper
• The Role of Incretins on Insulin Function and Glucose Homeostasis

  2021cites this paper
• Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice

  2021cites this paper
• An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.

  2021cites this paper
• Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches

  2020cites this paper
• Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease.

  2020cites this paper
• GIP's involvement in the pathophysiology of type 2 diabetes.

  2020cites this paper
• GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers

  2020cites this paper
• GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review

  2020cites this paper
• Leveraging the Gut to Treat Metabolic Disease.

  2020cites this paper
• From Entero-Endocrine Cell Biology to Surgical Interventional Therapies for Type 2 Diabetes.

  2020cites this paper
• Islet cell dysfunction in patients with chronic pancreatitis

  2020cites this paper
• Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes

  2020cites this paper
• On Meal Effects and DPP-4 Inhibition Islet- and Incretin Hormones in Health and Type 2 Diabetes

  2020cites this paper
• Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment

  2019cites this paper
• Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications.

  2019cites this paper
• Inkretinbasierte Ko- und Triagonisten

  2019cites this paper
• The incretin system in healthy humans: The role of GIP and GLP-1.

  2019cites this paper
• From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy

  2019cites this paper
• GLP-1R is downregulated in beta cells of NOD mice and T1D patients

  2019influential citation
• The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect

  2019cites this paper
• Assessment of Islet Alpha- and Beta-Cell Function

  2019cites this paper
• Incretin therapy for diabetes mellitus type 2.

  2019cites this paper
• GIP analogues and the treatment of obesity-diabetes.

  2019cites this paper
• Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists.

  2019cites this paper
• Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

  2019cites this paper
• Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities

  2019cites this paper
• Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals

  2019cites this paper
• Incretin Hormones and Insulin Responses During OGTT in Newly Diagnosed T2DM Patients

  2018cites this paper
• A novel GIP analogue, ZP4165, enhances glucagon‐like peptide‐1‐induced body weight loss and improves glycaemic control in rodents

  2018cites this paper
• The GLP-1 response to glucose does not mediate beta and alpha cell dysfunction in Hispanics with abnormal glucose metabolism.

  2018cites this paper
• Enteroendocrine K and L cells in healthy and type 2 diabetic individuals

  2018cites this paper
• Behavioural and Pharmacological Interactions between Drug and Nutritional Reinforcers

  2018cites this paper
• Tratamiento con agonistas del receptor del GLP-1 en pacientes con Diabetes Mellitus Tipo 2 en la práctica clínica habitual

  2018cites this paper
• Chapter 2 Incretin hormones as a target for therapy

  2018cites this paper
• Exendin‐4(Lys27PAL)/gastrin/xenin‐8‐Gln: A novel acylated GLP‐1/gastrin/xenin hybrid peptide that improves metabolic status in obese‐diabetic (ob/ob) mice

  2018cites this paper
• Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery

  2017influential citation
• Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors.

  2017cites this paper
• Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.

  2017cites this paper
• Exploring the effects of DPP‐4 inhibitors on the kidney from the bench to clinical trials

  2017cites this paper
• Glucose dependent insulinotropic polypeptide and dipeptidyl peptidase inhibitors: Their roles in management of type 2 diabetes mellitus.

  2016cites this paper
• Naturally-occurring TGR5 agonists modulating glucagon-like peptide-1 biosynthesis and secretion.

  2016cites this paper
• Third Exposure to a Reduced Carbohydrate Meal Lowers Evening Postprandial Insulin and GIP Responses and HOMA-IR Estimate of Insulin Resistance

  2016cites this paper
• Searching for the physiological role of glucose‐dependent insulinotropic polypeptide

  2016cites this paper
• The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.

  2016cites this paper
• Splanchnic Metabolism and Blood Flow In Man. PET Studies with Reference to Obesity and Diabetes

  2016cites this paper
• Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells.

  2016influential citation
• Long-Term Exposure of Pancreatic β-Cells to Palmitate Results in SREBP-1C-Dependent Decreases in GLP-1 Receptor Signaling via CREB and AKT and Insulin Secretory Response.

  2016cites this paper
• Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

  2016cites this paper
• Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor.

  2016cites this paper
• Chapter 40 – Type 2 Diabetes Mellitus: Etiology, Pathogenesis, and Natural History

  2016cites this paper
• BASIC AND TRANSLATIONAL—PANCREAS Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by a Cells

  2016cites this paper
• Reappraisal of GIP Pharmacology for Metabolic Diseases.

  2016cites this paper
• Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’

  2016cites this paper
• Incretin hormones as a target for therapy

  2016cites this paper
• Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition

  2016cites this paper
• Pursuit of a perfect insulin

  2016cites this paper
• Effects of glucose-dependent insulinotropic polypeptide on glucagon

  2016cites this paper
• Decreased insulin secretion and glucose clearance in exocrine pancreas‐insufficient pigs

  2016cites this paper
• Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness.

  2015cites this paper
• Differential molecular and cellular responses of GLP-1 secreting L-cells and pancreatic alpha cells to glucotoxicity and lipotoxicity.

  2015cites this paper
• Glucose metabolism and production of incretins in patients with obesity and type 2 diabetes mellitus after Biliopancreatic bypass surgery in the modification of Hess-Marceau the early stages of postoperative monitoring

  2015cites this paper
• Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study

  2015cites this paper
• Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors

  2015cites this paper
• II-3．インクレチン関連薬による膵性糖尿病の治療

  2015cites this paper